Join Daniel Coyne, MD as he shares the results of an important new clinical trial, Dialysis Patients' Response to IV Iron With Elevated Ferritin (DRIVE), and examines the safety and efficacy of sodium ferric gluconate in managing the anemic hemodialysis patient who is receiving adequate epoetin treatment, with a serum ferritin of 500 ng/mL to 1200 ng/mL and TSAT of ≤25%. You will find the results to be impressive.